Mans Keri, Kettner Hannes, Erritzoe David, Haijen Eline C H M, Kaelen Mendel, Carhart-Harris Robin L
Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom.
Front Psychiatry. 2021 Jun 29;12:647909. doi: 10.3389/fpsyt.2021.647909. eCollection 2021.
In the last 15 years, psychedelic substances, such as LSD and psilocybin, have regained legitimacy in clinical research. In the general population as well as across various psychiatric populations, mental well-being has been found to significantly improve after a psychedelic experience. Mental well-being has large socioeconomic relevance, but it is a complex, multifaceted construct. In this naturalistic observational study, a comprehensive approach was taken to assessing well-being before and after a taking a psychedelic compound to induce a "psychedelic experience." Fourteen measures of well-being related constructs were included in order to examine the breadth and specificity of change in well-being. This change was then analysed to examine clusters of measures changing together. Survey data was collected from volunteers that intended to take a psychedelic. Four key time points were analysed: 1 week before and 2 weeks, 4 weeks, and 2 years after the experience ( = 654, = 315, = 212, and = 64, respectively). Change on the included measures was found to cluster into three factors which we labelled: 1) "Being well", 2) "Staying well," and 3) "Spirituality." Repeated Measures Multivariate Analysis of Variance revealed all but the spirituality factor to be improved in the weeks following the psychedelic experience. Additional Mixed model analyses revealed selective increases in and (but not ) that remained statistically significant up to 2 years post-experience, albeit with high attrition rates. examination suggested that attrition was not due to differential acute experiences or mental-health changes in those who dropped out vs. those who did not. These findings suggest that psychedelics can have a broad, robust and sustained positive impact on mental well-being in those that have a prior intention to use a psychedelic compound. Public policy implications are discussed.
在过去15年里,诸如麦角酸二乙酰胺(LSD)和裸盖菇素等致幻物质在临床研究中重新获得了合法性。在普通人群以及各类精神疾病人群中,人们发现经历一次致幻体验后心理健康状况有显著改善。心理健康具有重大的社会经济意义,但它是一个复杂、多方面的概念。在这项自然主义观察研究中,采用了一种综合方法来评估服用致幻化合物以引发“致幻体验”前后的幸福感。纳入了14项与幸福感相关概念的测量指标,以检验幸福感变化的广度和特异性。然后对这种变化进行分析,以检查共同变化的测量指标集群。从打算服用致幻剂的志愿者那里收集了调查数据。分析了四个关键时间点:体验前1周以及体验后2周、4周和2年(分别为n = 654、n = 315、n = 212和n = 64)。在所纳入的测量指标上的变化被发现聚为三个因素,我们将其标记为:1)“状态良好”,2)“保持良好”,3)“精神性”。重复测量多元方差分析显示,除了精神性因素外,在致幻体验后的几周内其他因素都有所改善。额外的混合模型分析显示,幸福感(SWB)和生活满意度(LS)有选择性增加(但不是生活意义感[ML]),这种增加在体验后长达2年都保持统计学显著,尽管损耗率很高。脱落分析表明,脱落并非由于退出者与未退出者在急性体验或心理健康变化方面存在差异。这些发现表明,致幻剂对那些事先有意使用致幻化合物的人的心理健康可能会产生广泛、有力且持续的积极影响。文中还讨论了对公共政策的影响。